No Additional Anticoagulation Needed During Hospitalization
A patient already on rivaroxaban (Xarelto) 15 mg daily for heart rhythm issues does NOT require additional anticoagulation while hospitalized, provided they continue taking their home dose and have no contraindications.
Rationale
The rivaroxaban 15 mg daily dose indicates this patient likely has:
- Atrial fibrillation with moderate renal impairment (CrCl 30-49 mL/min) 1, 2, OR
- Recent acute coronary syndrome/PCI as part of dual pathway therapy 3, 4
In either scenario, this is a therapeutic anticoagulation dose, not prophylactic dosing.
Key Management Principles
Continue Home Anticoagulation
- Rivaroxaban should be continued uninterrupted during hospitalization unless the patient requires an invasive procedure or develops active bleeding 1
- The 15 mg daily dose provides full anticoagulant effect for stroke prevention in AF or thromboembolism prevention 1, 2
No Bridging Therapy Required
There is no indication for heparin bridging (UFH or LMWH) in hospitalized patients on therapeutic DOACs 1. The French Working Group on Perioperative Hemostasis explicitly states: "There is no need for preoperative heparin bridging (UFH or LMWH) except for very thrombotic high-risk" 1.
VTE Prophylaxis Considerations
- Do NOT add prophylactic LMWH or heparin on top of rivaroxaban - this creates unnecessary bleeding risk
- The therapeutic dose of rivaroxaban already provides superior VTE prophylaxis compared to standard prophylactic anticoagulation
- If the patient cannot take oral medications temporarily, hold rivaroxaban rather than stacking anticoagulants
Critical Exceptions Requiring Temporary Discontinuation
Before Invasive Procedures
Timing depends on bleeding risk and renal function 1, 5, 1:
For LOW bleeding risk procedures:
- Normal/mild renal impairment (CrCl ≥50 mL/min): Last dose 2 days before (skip 1 dose) 5
- Moderate renal impairment (CrCl 30-50 mL/min): Last dose 2 days before (skip 1 dose) 5
For HIGH bleeding risk procedures:
- Normal/mild renal impairment: Last dose 3 days before (skip 2 doses) 5
- Moderate renal impairment: Last dose 3 days before (skip 2 doses) 5
- Severe renal impairment (CrCl 15-30 mL/min): Last dose 4 days before (skip 3 doses) 5
Very high-risk procedures (intracranial neurosurgery, neuraxial anesthesia): May require up to 5 days interruption 1
Resumption After Procedures
- Start prophylactic LMWH/heparin at least 6 hours post-procedure if VTE prophylaxis indicated 1
- Resume therapeutic rivaroxaban 24-72 hours post-procedure once surgical hemostasis achieved 1
- Give first therapeutic dose 12 hours after last prophylactic LMWH 1
Common Pitfalls to Avoid
- Do NOT stack anticoagulants: Adding prophylactic heparin to therapeutic rivaroxaban dramatically increases bleeding risk without benefit
- Do NOT use rivaroxaban 2.5 mg BID: This ultra-low dose is only for specific ACS indications combined with antiplatelet therapy, NOT for AF stroke prevention 2, 4
- Do NOT routinely bridge with heparin: Unlike warfarin, rivaroxaban has rapid onset/offset and doesn't require bridging 1
- Verify renal function: The 15 mg dose is appropriate for CrCl 30-49 mL/min in AF; if renal function worsens below 30 mL/min, rivaroxaban may need adjustment or discontinuation 1, 2
If Patient Cannot Take Oral Medications
Temporarily hold rivaroxaban - there is no IV equivalent. Consider:
- Short interruptions (<24-48 hours): Generally safe without bridging for most patients 1
- Prolonged NPO status: Evaluate individual thrombotic risk (CHA₂DS₂-VASc score for AF patients) to determine if temporary UFH/LMWH bridging needed 1
Monitoring Considerations
- No routine coagulation monitoring required for rivaroxaban 2, 6
- Monitor renal function if clinical condition changes, as rivaroxaban is renally cleared 1
- Watch for bleeding signs: Rivaroxaban has no specific reversal agent readily available (though PCC can be considered for life-threatening bleeding) 7